Post entry

Laquinimod – Tevas självklara efterträdare!

Artikel idag

Teva and Active Biotech are also looking to bring their new MS treatment Laquinimod to the market for 2012. The drug is forecast to be making $600 million in peak annual sales, but received a blow when a recent Phase III trial showed that it failed to reduce relapse rates in MS patients compared to placebo.

Teva is looking to the drug as a successor to its current injectable MS drug Copaxone (glatiramer acetate), which made the firm $3.3 billion last year.

Scrolla ner på sidan så får du ovan skrivna text.

Aktien kommer inte att stanna vid 170 SEK

– 300 SEK är mer tänkbart...

Jag kan bara säga: KÖP!




You need to to read and post comments.

Does this article violate Redeye’s Rules & Guidelines?